의사-제약회사 상호작용이 처방에 미치는 영향
The Impact of Physician-Pharmaceutical Industry Interactions on Physician Prescriptions
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
The relationship between the medical profession and the pharmaceutical industry has received considerable attention in recent years in Korea. In this article we examine the impact of physicianpharmaceutical industry interaction (PPII) on physician prescriptions. While physicians’ decisions concerning prescriptions are influenced by many factors, two of the most influential are the visits of sales representatives from pharmaceutical companies and the gifts and other enticements that pharmaceutical companies provide for physicians. Patients regard gifts from pharmaceutical companies as less appropriate and more influential than do physicians. Inappropriate relations between physicians and pharmaceutical companies can damage physician-patient relationships and harm the medical profession as a whole. Recent investigations in the United States and Korea have found many illegalities in physician-pharmaceutical industry interaction. The article argues for the urgent need to develop clear ethical codes and compliance mechanisms concerning PPII.
Abstract
The relationship between the medical profession and the pharmaceutical industry has received considerable attention in recent years in Korea. In this article we examine the impact of physicianpharmaceutical industry interaction (PPII) on physician prescriptions. While physicians’ decisions concerning prescriptions are influenced by many factors, two of the most influential are the visits of sales representatives from pharmaceutical companies and the gifts and other enticements that pharmaceutical companies provide for physicians. Patients regard gifts from pharmaceutical companies as less appropriate and more influential than do physicians. Inappropriate relations between physicians and pharmaceutical companies can damage physician-patient relationships and harm the medical profession as a whole. Recent investigations in the United States and Korea have found many illegalities in physician-pharmaceutical industry interaction. The article argues for the urgent need to develop clear ethical codes and compliance mechanisms concerning PPII.
참고문헌 (26)
- Avorn J, "Scientific versus commercial sources of influence on the prescribing behaviour of physicians", Am J Med, 73, pp.4~8 (1982)
- Bloor K, "Lessons from international experience in controlling pharmaceutical expenditure II: Influencing doctors", BMJ, 312, pp.1525~1527 (1996)
- Campbell EG, "A national survey of physician-industry relationships", N Engl J Med, 356(17), pp.1742~1750 (2007)
- Chren MM, "Doctors, drug companies, and", JAMA, 262(24), pp.3448~3451 (1989)
- Chren MM, "Physician’s behavior and their interaction with drug company", JAMA, 271, pp.684~689 (1994)
- Coleman JS, "Medical Innovation- A Diffusion study" (1966), Bobbs-Merril
- Feely J, "The influence of hospital based prescribers on prescribing in general practice", Pharmacoeconomics, 16, pp.175~181 (1999)
- Gibbons RV, "A comparison of physicians’and patients’attitudes toward pharmaceutical industry gifts", J Gen Intern Med, 13(3), pp.151~154 (1998)
- Granja M, "Dangerous liaisons-physicians and pharmaceutical sales representatives", Acta Med Port, 18(1), pp.61~68 (2005)
- Hassel K, "Cost to patient or cost to the healthcare system? Which one matters the most for GP prescribing decisions? A UK-Italy comparison", Eur J Public Health, 13(1), pp.18~23 (2003)
- Hodges B, "Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks", CMAJ, 153, pp.553~559 (1995)
- Katz D, "All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry giftgiving", Am J Bioethics, 3(3), pp.39~46 (2003)
- McKoy JM, "Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Suppliers of Prostate Cancer Drugs", J Clin Oncol, 23(34), pp.8894~8905 (2005)
- Orlowski JP, "The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch", Chest, 102, pp.270~273 (1992)
- Peay M, "The role of commercial sources in the adoption of a new drug", Soc Sci Med, 26, pp.1183~1189 (1988)
- "Problems of Irrational Drug Use-Session Guide"[URL]
- Prosser H, "Influences on GPs’decision to prescribe new drugs ? the importance of who says what", Family Practice, 20(1), pp.61~68 (2003)
- Shaughnessy AF, "Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion", J Gen Intern Med, 9(10), pp.563~568 (1994)
- Sondergaard J, "Impact of pharmaceutical representative visits on GPs’drug preferences", Family Pract, 26(3), pp.204~209 (2009)
- Wazana A, "Physicians and the pharmaceutical industry: is a gift ever just a gift?", JAMA, 283, pp.373~380 (2000)
- Winik C, "The diffusion of an innovation among physicians in a large city", Sociometry, 24, pp.384~ (1961)
- Woollard RF, "Addressing the pharmaceutical industry’s influence on professional behavior", CMAJ, 149, pp.403~404 (1993)
- 건강보험심사평가원, "처방전당 약품목수 평가결과 공개", ~ (2008)
- 고윤석, "우리나라 의과대학병원 교수들의 의료윤리 문제들에 대한 견해", 한국의료윤리학회지, 7(2), pp.130~140 (2004), 한국의료윤리학회
- 공정거래위원회, "7개 제약회사의 부당고객유인행위 등에 대한 조치결과. 2009. 1. 15. 보도자료", ~ (2009)
- 하재건, "우리나라의 제약산업 발전방향에 관한 연구", 석사, pp.2010